4.7 Article

Abrupt Emergence of a Single Dominant Multidrug-Resistant Strain of Escherichia coli

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 207, Issue 6, Pages 919-928

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jis933

Keywords

Escherichia coli infections; antimicrobial resistance; extended-spectrum beta-lactamase; CTX-M-15; fluoroquinolone resistance; multidrug resistance; sequence type ST131; multilocus sequence typing; molecular epidemiology; FimH

Funding

  1. Office of Research and Development, Medical Research Service, Department of Veterans Affairs, Merit Review grant [1 I01 CX000192 01]
  2. NIH ARRA [1RC4AI092828]
  3. Cepheid
  4. Rib-X Pharmaceuticals
  5. Merck
  6. Rochester Medical
  7. Syntiron
  8. Direction de la Recherche Clinique AP-HP
  9. Group Health
  10. ARC Linkage
  11. Achaogen
  12. Cubist
  13. Affinium
  14. Sunovion
  15. Pfizer

Ask authors/readers for more resources

Background. Fluoroquinolone-resistant Escherichia coli are increasingly prevalent. Their clonal origins-potentially critical for control efforts-remain undefined. Methods. Antimicrobial resistance profiles and fine clonal structure were determined for 236 diverse-source historical (1967-2009) E. coli isolates representing sequence type ST131 and 853 recent (2010-2011) consecutive E. coli isolates from 5 clinical laboratories in Seattle, Washington, and Minneapolis, Minnesota. Clonal structure was resolved based on fimH sequence (fimbrial adhesin gene: H subclone assignments), multilocus sequence typing, gyrA and parC sequence (fluoroquinolone resistance-determining loci), and pulsed-field gel electrophoresis. Results. Of the recent fluoroquinolone-resistant clinical isolates, 52% represented a single ST131 subclonal lineage, H30, which expanded abruptly after 2000. This subclone had a unique and conserved gyrA/parC allele combination, supporting its tight clonality. Unlike other ST131 subclones, H30 was significantly associated with fluoroquinolone resistance and was the most prevalent subclone among current E. coli clinical isolates, overall (10.4%) and within every resistance category (11%-52%). Conclusions. Most current fluoroquinolone-resistant E. coli clinical isolates, and the largest share of multidrug-resistant isolates, represent a highly clonal subgroup that likely originated from a single rapidly expanded and disseminated ST131 strain. Focused attention to this strain will be required to control the fluoroquinolone and multidrug-resistant E. coli epidemic.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available